Publications by authors named "R Vile"

Claim this Profile
T
T cell exhaustion in poorly immunogenic HCC is partially rescued by checkpoint blockade but suppressed by oncolytic virotherapy.
Thanich Sangsuwannukul, Benjamin Kendall, Jason Tonne, Olivia Liseth, Jill Thompson, Richard G Vile

Mol Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting viral infection/vaccination to focus high-affinity T cell populations into tumors using oncolytic viro-immunotherapy.
Alexa Veliz Rios, Muriel Metko, Jason Tonne, Jill Thompson, Benjamin Kendall, Richard Vile

Mol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fusing Oncolytic Virotherapy With Cancer Immunotherapy to Treat Therapy-Resistant Melanoma.
Richard G Vile

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic viruses as anticancer agents: clinical progress and remaining challenges.
Elizabeth Appleton, E Antonio Chiocca, Guy Ungerechts, Alan Melcher, Richard Vile

Lancet· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeat Systemic Delivery of Cross-Neutralization Resistant Synthetic Vesiculoviruses Immunomodulates the Tumor Microenvironment.
Natalie M Elliott, Benjamin L Kendall, Souyma Dutta, Daipayan Sarkar, John W Vant, Richard Vile

bioRxiv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis